NGM·Healthcare·$587M·#356 / 520 in Healthcare
ALT Altimmune, Inc.
33HIGH RISK
CATEGORY BREAKDOWN
GROWTH100
QUALITY0
STABILITY42
VALUATION0
GOVERNANCE2
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+105.0%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
8 months
19
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
15.9%
87
< 25% strong
Price / Sales
Market cap relative to trailing revenue
14315.9x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-230356
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.4%
3
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+149.7%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ALT WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when ALT's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.